首页> 外文期刊>Thoracic cancer. >Should the clinical significance of supraclavicular and celiac lymph node metastasis in thoracic esophageal cancer be reevaluated?
【24h】

Should the clinical significance of supraclavicular and celiac lymph node metastasis in thoracic esophageal cancer be reevaluated?

机译:是否应该重新评估胸部食管癌中患者和腹腔淋巴结转移的临床意义吗?

获取原文
           

摘要

Lower thoracic esophageal cancer (LTEC) with celiac node metastasis and upper thoracic esophageal cancer (UTEC) with supraclavicular node metastasis were previously categorized as M1a diseases. Our study aimed to investigate whether the clinical significance of supraclavicular and celiac lymph node metastasis should be reevaluated in thoracic esophageal cancer. A total of 6178 patients with thoracic esophageal cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database during 2004-2015. Treatment strategies and outcomes (OS, overall survival; CSS, cancer-specific survival) of patients with different nodal status were reviewed. The Cox proportional hazards regression model was applied to evaluate the prognostic factors. Statistical analyses were performed in all subgroups. Multivariate analysis identified supraclavicular node metastasis but not celiac node metastasis as an independent predictor of both OS and CSS in LTEC. However, metastasis to supraclavicular or celiac nodes was not an independent predictor of OS and CSS in UTEC. Surgery was not associated with increased OS and CSS for UTEC with celiac or supraclavicular node metastasis but was favored as a predictor of better OS and CSS for LTEC with celiac or supraclavicular node metastasis. Radiotherapy benefited OS and CSS in LTEC involving celiac or supraclavicular nodes and in UTEC involving celiac nodes, while only OS benefited from radiotherapy in UTEC involving supraclavicular nodes. These results provide preliminary evidence that the clinical significance of supraclavicular and celiac lymph node metastasis should be reevaluated in thoracic esophageal cancer with different prognostic information according to the primary sites. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译:将胸腔食管癌(LTEC)与腹腔节点转移和上胸部食管癌(UTEC)的降低胸部食管癌(UTEC)预先作为M1A疾病进行分类。我们的研究旨在探讨Supracatulular和乳糜泻淋巴结转移的临床意义是否应在胸部食管癌中重新评估。在2004 - 2015年期间,共鉴定了6178例胸部食管癌患者的监测,流行病学和最终结果(SEER)数据库。综述了治疗策略和结果(OS,总体存活率; CSS,癌症特异性生存期)进行了综述。施用Cox比例危害回归模型来评估预后因素。在所有亚组中进行统计分析。多变量分析鉴定了Suprachavicular节点转移,但不是腹腔节点转移作为LTEC中的OS和CSS的独立预测因子。然而,转移到Supractavicular或乳糜烃节点不是UTEC中OS和CSS的独立预测因子。手术与UTEC的含量和CSS的增加与腹腔或上皮细胞节点转移无关,但是有利于用腹腔或上皮细胞节点转移的LTEC更好的OS和CSS的预测因子。放射疗法在LTEC中涉及乳糜泻或患有乳糜泻的UTEC中的OS和CSS,而涉及乳糜泻的UTEC,而涉及Suprachular节点的UTEC中的放射疗法受益。这些结果提供了初步证据证明,根据主要部位的不同预后信息,应在胸部食管癌中重新评估患者和乳糜泻淋巴结转移的初步证据。 ? 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号